BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260922T123000
DTEND;TZID=America/New_York:20260922T140000
DTSTAMP:20260819T232152
CREATED:20260806T175325Z
LAST-MODIFIED:20260819T191902Z
UID:3271-1790080200-1790085600@lifescievents.com
SUMMARY:Rapport Therapeutics Virtual KOL Event: The Unmet Need in Bipolar Disorder
DESCRIPTION:Join Rapport Therapeutics for a virtual key opinion leader (KOL) event featuring Mauricio Tohen\, MD\, DrPH\, MBA (University of New Mexico Health Science Center)\, and Gary Sachs\, MD (Massachusetts General Hospital\, Harvard Medical School)\, who will join company management to discuss the unmet need and current treatment landscape for bipolar mania. \nThe event will provide an overview of RAP-219\, the Company’s clinical-stage TARPγ8-specific AMPA receptor (AMPAR) negative allosteric modulator (NAM) currently in development as a potential first-in-class treatment for patients with bipolar mania. The compound is also being studied as a potential treatment for drug-resistant focal onset seizures\, with Phase 3 trials underway. A Phase 2 trial in patients with bipolar mania is ongoing\, with topline data expected in October 2026. \nTopics will include the underlying biology of bipolar mania and mechanistic rationale for RAP-219 as a potential treatment; challenges of treating bipolar mania patients\, including limitations of the current standard of care; and the need for well-tolerated\, effective new treatment options. Drs. Tohen and Sachs will also discuss the ongoing RAP-219 Phase 2 trial in bipolar mania\, including practicing physicians’ perspectives on the efficacy and tolerability profile needed in a new treatment and what would define a successful trial outcome. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/rwo28yp/.
URL:https://lifescievents.com/event/rwo28yp/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/08/Events-Banners_2-3-1.png
END:VEVENT
END:VCALENDAR